Heterodimeric antibodies to CD3 X CD123

Patent metadata

Field	Value
Publication number	US-9856327-B2
Application number	US-201615186167-A
Country	US
Kind code	B2
Filing date	Jun 17, 2016
Priority date	Nov 26, 2014
Publication date	Jan 2, 2018
Grant date	Jan 2, 2018

Abstract

The present invention is directed to novel heterodimeric antibodies.

First claim

What is claimed is:

1. A heterodimeric antibody comprising:
a) a first monomer comprising SEQ ID NO:468;
b) a second monomer comprising SEQ ID NO:469; and
c) a light chain comprising SEQ ID NO:470.

2. A nucleic acid composition comprising:
a) a first nucleic acid sequence encoding SEQ ID NO:468;
b) a second nucleic acid sequence encoding SEQ ID NO:469; and
c) a third nucleic acid sequence encoding SEQ ID NO:470.

3. An expression vector composition comprising:
a) a first expression vector comprising a first nucleic acid sequence encoding SEQ ID NO:468;
b) a second expression vector comprising a second nucleic acid sequence encoding SEQ ID NO:469; and
c) a third expression vector comprising a third nucleic acid sequence encoding SEQ ID NO:470.

4. A host cell comprising the expression vector composition of claim 3 .

5. A method of treating leukemia in a patient comprising administering the heterodimeric antibody according to claim 1 to said patient.

Assignees

• Xencor Inc

Inventors

• Bernett Matthew J
• Moore Gregory
• Desjarlais John
• Chu Seung
• Rashid Rumana
• Muchhal Umesh
• Lee Sung-Hyung

Classifications

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K16/2809

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K16/3061

  Blood cells · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/55

  Fab or Fab' · CPC title